D. E. Shaw & Co., Inc. Nektar Therapeutics Call Options Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $473,700 - $695,250	-15,000 Reduced 25.0%	45,000 $1.51 Million
Q4 2018 Feb 14, 2019	BUY	$30.43 - $56.65 $456,450 - $849,750	15,000 Added 33.33%	60,000 $1.97 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $462,500 - $1.04 Million	10,000 Added 28.57%	45,000 $2.2 Million
Q1 2018 May 15, 2018	BUY	$57.4 - $108.44 $1.44 Million - $2.71 Million	25,000 Added 250.0%	35,000 $3.72 Million
Q4 2017 Feb 14, 2018	BUY	$23.02 - $60.5 $230,200 - $605,000	10,000	10,000 $597,000

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.